Biogen Inc Stock Today

BIIB Stock  USD 143.46  2.19  1.55%   

Performance

Very Weak

 
Weak
 
Strong

Odds Of Distress

Low

 
High
 
Low
Biogen is trading at 143.46 as of the 25th of February 2025, a 1.55 percent increase since the beginning of the trading day. The stock's open price was 141.27. Biogen has only a 6 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. Note, on December 6, 2024, Representative Ro Khanna of US Congress acquired under $15k worth of Biogen Inc's common stock.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
16th of September 1991
Category
Healthcare
Classification
Health Care
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts. Biogen operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. The company has 146.38 M outstanding shares of which 3.74 M shares are currently shorted by private and institutional investors with about 2.92 trading days to cover. More on Biogen Inc

Moving against Biogen Stock

  0.73PHGE Biomx IncPairCorr
  0.71OPT Opthea Earnings Call TomorrowPairCorr
  0.68GANX Gain TherapeuticsPairCorr
  0.65LTRN Lantern PharmaPairCorr
  0.51FENC Fennec PharmaceuticalsPairCorr
  0.48CUE Cue BiopharmaPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Biogen Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEO PresidentChristopher Viehbacher
Thematic IdeaHedge Favorites (View all Themes)
Old NameBiogen Inc
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, Nasdaq 100, SP 500 Index, NASDAQ 100 Equal, Nasdaq 100 Total, ARCA Biotechnology, Dow Jones Biotechnology, NASDAQ 100 Pre, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Hedge Favorites, Health Care, Biotechnology, Drug Manufacturers—General, Healthcare (View all Sectors)
Excise Tax ActivitiesAnimal Testing
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.340.345
Fairly Down
Slightly volatile
Gross Profit Margin0.510.67
Way Down
Slightly volatile
Total Current Liabilities5.8 B5.5 B
Sufficiently Up
Slightly volatile
Non Current Liabilities Total3.2 B5.8 B
Way Down
Slightly volatile
Total Assets29.5 B28 B
Sufficiently Up
Slightly volatile
Total Current Assets7.8 B7.5 B
Sufficiently Up
Slightly volatile
Debt Levels
Biogen can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Biogen's financial leverage. It provides some insight into what part of Biogen's total assets is financed by creditors.
Liquidity
Biogen Inc currently holds 6.63 B in liabilities with Debt to Equity (D/E) ratio of 0.52, which is about average as compared to similar companies. Biogen Inc has a current ratio of 2.44, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Biogen's use of debt, we should always consider it together with its cash and equity.

Change In Cash

1.39 Billion
Biogen Inc (BIIB) is traded on NASDAQ Exchange in USA. It is located in 225 Binney Street, Cambridge, MA, United States, 02142 and employs 7,605 people. Biogen is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 20.68 B. Biogen Inc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 146.38 M outstanding shares of which 3.74 M shares are currently shorted by private and institutional investors with about 2.92 trading days to cover. Biogen Inc currently holds about 4.91 B in cash with 2.88 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 34.1.
Check Biogen Probability Of Bankruptcy
Ownership Allocation
Biogen holds a total of 146.38 Million outstanding shares. The majority of Biogen Inc outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Biogen Inc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Biogen. Please pay attention to any change in the institutional holdings of Biogen Inc as this could imply that something significant has changed or is about to change at the company. On December 6, 2024, Representative Ro Khanna of US Congress acquired under $15k worth of Biogen Inc's common stock.
Check Biogen Ownership Details

Biogen Stock Institutional Holders

InstituionRecorded OnShares
T. Rowe Price Associates, Inc.2024-12-31
1.9 M
Morgan Stanley - Brokerage Accounts2024-12-31
1.8 M
Beutel, Goodman & Company Ltd.2024-12-31
1.7 M
D. E. Shaw & Co Lp2024-12-31
1.6 M
Northern Trust Corp2024-12-31
1.6 M
Ubs Asset Mgmt Americas Inc2024-12-31
1.5 M
Legal & General Group Plc2024-12-31
1.2 M
Amundi2024-12-31
1.2 M
Renaissance Technologies Corp2024-12-31
1.2 M
Vanguard Group Inc2024-12-31
16.7 M
Primecap Management Company2024-12-31
16 M
View Biogen Diagnostics

Biogen Historical Income Statement

At present, Biogen's Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to about 262.8 M, whereas EBIT is forecasted to decline to about 1.7 B. View More Fundamentals

Biogen Stock Against Markets

Biogen Corporate Executives

Elected by the shareholders, the Biogen's board of directors comprises two types of representatives: Biogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biogen. The board's role is to monitor Biogen's management team and ensure that shareholders' interests are well served. Biogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biogen's outside directors are responsible for providing unbiased perspectives on the board's policies.
Michael CPAExecutive CFOProfile
When determining whether Biogen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biogen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biogen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biogen Inc Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. If investors know Biogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.063
Earnings Share
11.18
Revenue Per Share
66.455
Quarterly Revenue Growth
0.029
Return On Assets
0.0529
The market value of Biogen Inc is measured differently than its book value, which is the value of Biogen that is recorded on the company's balance sheet. Investors also form their own opinion of Biogen's value that differs from its market value or its book value, called intrinsic value, which is Biogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biogen's market value can be influenced by many factors that don't directly affect Biogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.